Eupraxia Pharma Reports 12-Week And 36-Week Tissue Health Data From Ongoing Phase 1b/2a Part Of RESOLVE Trial Evaluating EP-104GI For Treatment Of Eosinophilic Esophagitis
Benzinga Newsdesk 10 months ago
News
At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health. At lower doses, patients maintained the improvements in tissue
- At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health.
- At lower doses, patients maintained the improvements in tissue health1 reported at week 12 out until week 36.
- Clinical remission2 was achieved by 8 weeks and maintained through 52 weeks in the majority of patients for which more than 60% of their esophagus was treated.
- EP-104GI continues to be well tolerated by patients receiving the drug; over 200 patient-months of follow-up have been reported with no Serious Adverse Events ("SAEs"), and no cases of oral candidiasis.
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced positive 12-week and 36-week tissue health data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE").